Identification of a novel series of potent RON receptor tyrosine kinase inhibitors

A novel series of N-(3-fluoro-4-(2-substituted-thieno[3,2- b]pyridin-7-yloxy)phenyl)-1-phenyl-5-(trifluoromethyl)-1 H-pyrazole-4-carboxamides targeting RON receptor tyrosine kinase was designed and synthesized. SAR study of the series allowed us to identify compounds possessing either inhibitory act...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Bioorganic & medicinal chemistry letters 2010-05, Vol.20 (9), p.2745-2749
Hauptverfasser: Raeppel, Stéphane, Gaudette, Frédéric, Mannion, Michael, Claridge, Stephen, Saavedra, Oscar, Isakovic, Ljubomir, Déziel, Robert, Beaulieu, Normand, Beaulieu, Carole, Dupont, Isabelle, Nguyen, Hannah, Wang, James, Macleod, A. Robert, Maroun, Christiane, Besterman, Jeffrey M., Vaisburg, Arkadii
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:A novel series of N-(3-fluoro-4-(2-substituted-thieno[3,2- b]pyridin-7-yloxy)phenyl)-1-phenyl-5-(trifluoromethyl)-1 H-pyrazole-4-carboxamides targeting RON receptor tyrosine kinase was designed and synthesized. SAR study of the series allowed us to identify compounds possessing either inhibitory activity of RON kinase enzyme in the low nanomolar range with low residual activity against the closely related c-Met or potent dual inhibitory activity against RON and c-Met, − with no significant activity against VEGFR2 in both cases. A novel series of N-(3-fluoro-4-(2-substituted-thieno[3,2- b]pyridin-7-yloxy)phenyl)-1-phenyl-5-(trifluoromethyl)-1 H-pyrazole-4-carboxamides targeting RON receptor tyrosine kinase was designed and synthesized. SAR study of the series allowed us to identify compounds possessing either inhibitory activity of RON kinase enzyme in the low nanomolar range with low residual activity against the closely related c-Met or potent dual inhibitory activity against RON and c-Met, − with no significant activity against VEGFR2 in both cases.
ISSN:0960-894X
1464-3405
DOI:10.1016/j.bmcl.2010.03.073